Skip to content

LSD: all studies

Page 239 of 282: studies 2,381 to 2,390 of 2,815, newest first. Back to the LSD overview

Research

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Journal of Psychopharmacology November 18, 2016 James Rucker, Luke A. Jelen, Sarah Kalen Flynn et al. 187 citations

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used...

Acid Hype: American News Media and the Psychedelic Experience

Journal of American History November 8, 2016 2 citations

In the popular imagination lsd (lysergic acid diethylamide) was introduced to the American public by radical figures such as Timothy Leary or Ken Kesey as part of the countercultural rebellion of the 1960s. Scholars have also written about the part played by mental health professionals and various government agencies in spreading knowledge about the psychedelic experience to certain sectors of...

Psychedelics as Medicines: An Emerging New Paradigm

Clinical Pharmacology & Therapeutics November 4, 2016 De Nichols, Mw Johnson, Cd Nichols 366 citations

Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT 2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that...

Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.

The American Journal of Drug and Alcohol Abuse November 1, 2016 Joseph J Palamar, Patricia Acosta, Scott J Sherman et al. 73 citations

Novel psychoactive substances (NPSs) continue to emerge in the United States and worldwide. Few epidemiological studies have examined the prevalence and correlates of use. We examined the extent of NPS use in a high-risk population-attendees of electronic dance music (EDM) parties at nightclubs and festivals. We surveyed 682 adults (age 18-25) entering EDM events at nightclubs and festivals in...

DOI: 10.1080/00952990.2016.1181179 (opens in new tab) Full text (opens in new tab) Novel psychoactive substances Synthetic cannabinoids Synthetic cathinones Young adults +13

Tripping the light fantastic: the phenomenon of the hallucinogens

October 14, 2016 Ilana Belle Glass 1 citation

The final quote is from Timothy Leary (1964), the psychologist turned guru who, during the 1960s, first exhorted youth to &s;tum on, tune in and drop out&s;. He and other members of the League of Spiritual Discovery (LSD) described how &s;a psychedelic journey is a journey to new realms of consciousness. The scope and content of the experience is limitless, but its characteristic features are...

Psilocybin as an alternative medicine for patients suffering from depression

Psychiatria i Psychologia Kliniczna September 30, 2016 Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz 2 citations

Psylocybina jest substancją psychodysleptyczną pochodzenia naturalnego, występuje w grzybach rodzaju Psilocybe. Psychodysleptyki są środkami psychoaktywnymi, które silnie wpływają na percepcję, nastrój i procesy poznawcze człowieka. Psychodeliczne działanie psylocybiny opiera się na pobudzaniu receptorów serotoninergicznych, co prowadzi do wzrostu stężenia serotoniny w mózgu oraz przyczynia się...

DOI: 10.15557/pipk.2016.0023 (opens in new tab) Psilocybin Depression economics Psychotherapist Hallucinogen

Psychedelic Psychotherapy: Insights From 25 Years of Research

Journal of Humanistic Psychology September 29, 2016 William A. Richards 70 citations

Presented at a conference titled “Psychedelic Science 2013,” highlighting the resumption of investigations with psychedelic substances (i.e., psilocybin, DMT, LSD, MMDA, etc.) in the United States and Europe after a dormant period of more than two decades, the author presents insights and perspectives gleaned from his 25 years of clinical research experience. After acknowledging the vastness...

DOI: 10.1177/0022167816670996 (opens in new tab) Psilocybin Psychotherapist Consciousness Psyche +7

Australia should be initiating a psychedelic research program: What are the barriers?

Australian & New Zealand Journal of Psychiatry September 28, 2016 N. Strauss, Stephen Bright, Martin L Williams 10 citations

Australian & New Zealand Journal of Psychiatry, 50(11) A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that...

Psychosis associated with acute recreational drug toxicity: a European case series.

BMC Psychiatry August 18, 2016 Odd Martin Vallersnes, Alison M. Dines, David M Wood et al.

Psychosis can be associated with acute recreational drug and novel psychoactive substance (NPS) toxicity. However, there is limited data available on how common this is and which drugs are most frequently implicated. We describe a European case series of psychosis associated with acute recreational drug toxicity, and estimate the frequency of psychosis for different recreational drugs. The...

DOI: 10.1186/s12888-016-1002-7 (opens in new tab) Full text (opens in new tab) Acute poisoning Acute toxicity Amphetamine Hallucinogens +5

Hallucinogen Persisting Perception Disorder and Risk of Suicide.

Journal of pharmacy practice August 2016 Joy Brodrick, Brian G Mitchell

A 30-year-old male patient developed a hallucinogen persisting perception disorder (HPPD) after smoking cannabis laced with phencyclidine (PCP) or lysergic acid diethylamide (LSD) 10 years prior to hospital admission. Clinically, he reported seeing vivid, saturated colors and caricature-like objects. The patient described perceiving objects or people in motion as moving faster than normal. He...